Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Wave Life Sciences (WVE) reported third-quarter 2026 financial results while advancing clinical programs for obesity and alpha-1 antitrypsin deficiency (AATD). Revenue rose to $13.2 million from $7.6 million a year earlier; net loss widened to $61.9 million from $53.9 million.
Planning is underway for a two-year WVE-006 registrational trial, with a one-year interim analysis for potential accelerated approval. WVE-007 Phase 2a monotherapy dosing is ongoing and its tirzepatide combination trial has begun. Wave expects a post-incretin maintenance trial and a WVE-008 clinical trial application in 4Q 2026.
Cash, cash equivalents and marketable securities totaled $431.0 million at September 30, excluding a $12 million GSK milestone due in 4Q 2026. Wave expects its existing resources to fund operations into 3Q 2028, excluding potential future GSK payments.
Wave Life Sciences (WVE) will review its third quarter 2026 financial results during a webcast and conference call on October 27, 2026. The event begins at 8:30 a.m. ET and will include business updates. An archived webcast will be available on the company’s website afterward.
Wave Life Sciences (WVE) will host a virtual Research Day on November 4, 2026, at 9:30 a.m. ET. Wave plans to share new data on its RNA medicines platform, including capabilities within and outside the liver, RNA interference, RNA editing and bifunctional approaches. Hepatologist Arun J. Sanyal will discuss PNPLA3 I148M liver disease and the opportunity for RNA editing correction. A webcast and subsequent archive will be available on Wave’s website.
Wave Life Sciences (WVE) is scheduled to participate in Chardan’s 10th Annual Healthcare Conference on October 20, 2026. President and CEO Paul Bolno will join the “RNA Medicines: Next-Generation RNA Therapeutics” panel in New York City at 9:45 a.m. ET. A live webcast will be available through the company website’s Investor Events page, with a replay available for a limited time afterward.
Wave Life Sciences (WVE) announced FDA alignment on key aspects of its planned WVE-006 approval pathway for alpha-1 antitrypsin deficiency (AATD). Planning is underway for a single, two-year registrational trial, a study intended to support potential full approval. A one-year interim analysis would support potential accelerated approval based on AATD biomarkers. Wave describes the design as avoiding a separate confirmatory trial.
The FDA supports Wave’s current LC-MS laboratory assay to measure normal M-AAT and mutant Z-AAT proteins in the program. WVE-006, an investigational RNA-editing treatment, is being evaluated in the ongoing Phase 1b/2a RestorAATion-2 trial in people with the homozygous Pi*ZZ mutation. Wave remains on track to share 600 mg monthly multidose cohort data in the fourth quarter of 2026. WVE-006 continues to be generally safe and well tolerated, with no liver toxicities.
Wave Life Sciences (WVE) announced GSK’s selection of a hepatology candidate for its development pipeline, triggering a $12 million milestone payment.
The candidate was developed using Wave’s proprietary SpiNA design GalNAc-siRNA, an RNA-based approach, under the companies’ research collaboration. Wave will receive the selection payment and is eligible for up to $330–$375 million in development, launch and commercial milestones for each collaboration program, plus tiered royalties on net sales. Wave is also advancing three additional collaboration programs toward potential candidate selection.
Wave Life Sciences (WVE) has initiated a placebo-controlled Phase 2a trial of WVE-007, an investigational GalNAc-siRNA targeting INHBE, in combination with weekly tirzepatide in adults living with obesity and type 2 diabetes.
The study will test 240 mg and 400 mg doses of WVE-007 plus tirzepatide in individuals with BMI 35–50 kg/m², using a 3:1 randomization to active versus placebo. Wave reports that WVE-007 has shown in clinical data the ability to induce fat loss without muscle loss, with a safety and tolerability profile that may enable once- or twice-yearly dosing. Preclinical data showed Wave’s INHBE GalNAc-siRNA doubled weight loss when combined with a GLP-1 versus GLP-1 alone and suggested potential to limit weight regain after GLP-1 cessation.
The Phase 2a combination study is part of the INLIGHT™ program, which also includes an ongoing 12‑month monotherapy Phase 2a trial and a planned maintenance trial in the second half of 2026 to assess WVE-007 for preserving weight loss after stopping incretin therapy.
Wave Life Sciences (WVE) appointed Monika Vnuk, MD, as Chief Business Officer, effective with her joining the company’s executive team in September 2026. She will lead business development, corporate development, and alliance management as Wave advances its RNA medicines pipeline.
Dr. Vnuk previously served as Senior Vice President, Global Head of Partnering and Business Development at Sanofi, Managing Director at Blackstone Life Sciences, and held senior business development roles at Pfizer, including Vice President, R&D Business Development, where she led negotiation of the global COVID‑19 vaccine partnership with BioNTech. Earlier in her career she worked in investment banking at Bank of America and at venture firm Oxford Bioscience Partners.
In connection with her appointment, Dr. Vnuk received an option to purchase 375,000 Wave common shares at an exercise price of $4.25 per share, granted on September 21, 2026, vesting over four years with 25% vesting on September 21, 2027 and the remainder in equal quarterly installments over the following three years, as an inducement grant under Nasdaq Listing Rule 5635(c)(4).
Wave Life Sciences (WVE) will participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on September 10, 2026 at 9:45 a.m. ET.
A live webcast and a time-limited replay will be available via the company’s Investor Events webpage.
Wave Life Sciences (NASDAQ: WVE) completed its redomiciliation, changing the parent company of the Wave group from a Singapore entity to a Delaware corporation through a scheme of arrangement under Section 210 of the Singapore Companies Act. The transaction was finalized after the close of trading on August 7, 2026 (Eastern Time), when all issued ordinary shares of Wave Life Sciences Ltd. were exchanged on a one-for-one basis for newly issued common shares of Wave Life Sciences, a Delaware corporation. According to Wave Life Sciences, its equity will continue to trade under the symbol “WVE”, with the new common stock beginning trading on NASDAQ on August 10, 2026, and the company does not anticipate any material impact on employees or day-to-day business.